iGRO™ is the only medical tool that gives evidence-based predictions for the first 12 months of growth hormone (GH) treatment, using pre-treatment data.
WHAT IS iGRO™?
iGRO™ is an easy-to-use Software Medical Device, available in various countries (in Europe, Latin America and Asia).
iGRO™ is an easy-to-use, web-based tool. No software installation is required.
iGRO™ can be used on computers, laptops, tablets.
All iGRO™ output tables and graphs can be saved and printed.
iGRO™ applies evidence-based, validated and peer-reviewed growth prediction algorithm models, developed using clinical data in the KIGS database (the Pfizer International Growth Database), to provide realistic and personalised growth targets — helping you to assess and optimise response to growth hormone treatment.
This international database contains growth data collected over a 25-year period from over 83,000 children who have received growth hormone treatment from 52 countries. These algorithms enable you to make a more accurate prediction, based on the gender, age and condition of a child; and monitor their response to treatment. Using this information you can identify any issues, confirm diagnoses and guide further treatment -offering personalised growth hormone treatment that is based on your patient’s needs.
iGRO™ is a web-based medical device tool that complies with all relevant European and local data protection regulations. It makes it easy to apply these algorithms in clinical practice — enabling physicians to predict how much a child may grow in the first and subsequent years of GH therapy.
It is designed to support physicians in calculating growth predictions for a range of pre-pubertal and pubertal patients, and provides evidence-based guidance and justification for GH treatment decisions.
iGRO™ can be used to calculate growth predictions for a range of patients.
For children with idiopathic growth hormone deficiency (IGHD)1 and children born small for gestational age (SGA):
- Predictions for the first to 8th pre-pubertal year of treatment
- Subsequent pre-pubertal years
- Total pubertal growth.
HOW DOES IT WORK?
Getting started is simple and all patient data is stored securely online. Standard baseline patient data can be entered before treatment begins and results are displayed in a clear, graphical format. iGRO™ enables you to make highly accurate growth predictions based on gender, age and condition of patients, and evaluate response after 12 months: helping you to manage patient expectations and optimise the treatment outcome.